Capricor, Replimune illustrate why FDA must listen to rare disease specialists

Summary

Capricor Therapeutics and Replimune held FDA advisory committee meetings last month, with outcomes highlighting the importance of FDA specialization in rare disease reviews. No specific drug names, indications, or decision outcomes are provided in the article.